FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.
What happened
FDA reviewed records the company submitted after FDA's March 25, 2024 request for records under section 704(a)(4). The records showed the company did not test each incoming component for identity, did not test ethanol for methanol, and had no quality unit. FDA placed the firm's products on Import Alert 66-40 on January 23, 2025.
What FDA found
The company did not test each incoming drug component for identity before use.
21 CFR 211.84(d)(1)The company did not test incoming ethanol for methanol, a toxic contaminant.
21 CFR 211.84(d)(1)The company had no quality control unit with authority to approve or reject materials and products.
21 CFR 211.22(a)
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also recommends a qualified CGMP consultant and a six-system audit.
Who should pay attention
- brands and importers sourcing OTC drugs or hand sanitizer from this firm
- US distributors and retailers of hand sanitizers
- companies relying on supplier certificates of analysis for drug ingredients
This is a summary. Read the original letter on fda.gov.